Asthma and coagulation

Blood

Volumn 119, Issue 14, 2012, Pages 3236-3244

  De Boer, J Daan ^a   Majoor, Christof J ^a   Van 't Veer, Cornelis ^a   Bel, Elisabeth H D ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; DROTRECOGIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ASTHMA; BLOOD CLOTTING; DISEASE SEVERITY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LUNG; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

EID: 84859609314     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-391532     Document Type: Review

References (102)

1. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011. Available from: http://www.ginasthma. org.
2. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol. 1999;103(4):539-547. (Pubitemid 29295555)
3. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522-543. (Pubitemid 43340215)
4. Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66(10): 910-917.
5. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci. 2010; 31(7):335-343.
6. Levi M, Schultz MJ, Rijneveld AW, et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med. 2003; 31(4 suppl):S238-S242. (Pubitemid 36458173)
7. Levi M, Van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 suppl):S26-S34.
8. Wygrecka M, Jablonska E, Guenther A, et al. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost. 2008;99(3): 494-501. (Pubitemid 351549285)
9. Perrio MJ, Ewen D, Trevethick MA, et al. Fibrin formation by wounded bronchial epithelial cell layers in vitro is essential for normal epithelial repair and independent of plasma proteins. Clin Exp Allergy. 2007;37(11):1688-1700. (Pubitemid 47609854)
10. Wagers SS, Norton RJ, Rinaldi LM, et al. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyper-responsiveness. J Clin Invest. 2004;114(1):104- 111.
11. Gabazza EC, Taguchi O, Tamaki S, et al. Thrombin in the airways of asthmatic patients. Lung. 1999;177(4):253-262. (Pubitemid 29328201)
12. Kanazawa H, Yoshikawa T. Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways. Chest. 2007; 132(4):1169-1174. (Pubitemid 47620989)
13. Terada M, Kelly EAB, Jarjour NN. Increased thrombin activity after allergen challenge: a potential link to airway remodelling? Am J Respir Crit Care Med. 2004;169(3):373-377. (Pubitemid 38134817)
14. Schouten M, Van de Pol MA, Levi M, et al. Early activation of coagulation after allergen challenge in patients with allergic asthma. J Thromb Haemost. 2009;7(9):1592-1594.
15. Thomas VA, Wheeless CJ, Stack MS, et al. Human mast cell tryptase fibrinogenolysis: kinetics, anti-coagulation mechanism, and cell adhesion disruption. Biochemistry. 1998;24:37(8):2291- 2298.
16. Bastarache JD, Wang L, Geiser T, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax. 2007;62(7):608-616. (Pubitemid 47056889)
17. Brims JH, Chauhan AJ, Higgins BR, et al. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Thorax. 2009;64(12):1037-1043.
18. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood. 2007; 109(3):995-1002. (Pubitemid 46220644)
19. Sovershaev MA, Lind KF, Devold H, et al. No evidence for the presence of tissue factor in high-purity preparations of immunologically isolated eosinophils. J Thromb Haemost. 2008;6(10): 1742-1749.
20. .Wan H, Winton HL, Soeller C, et al. Der p1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest. 1999;104(1): 123-133. (Pubitemid 29534352)
21. Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009; 457(7229):585-588.
22. Epstein MM. Do mouse models of allergic asthma mimic clinical disease? Int Arch Allergy Immunol. 2004;133(1):84-100. (Pubitemid 38202239)
23. Hogan KA, Weiler H, Lord ST. Mouse models in coagulation. Thromb Haemost. 2002;87(4):563- 574.
24. Shinagawa K, Ploplis VA, Castellino FJ. A severe deficiency of coagulation factor VIIa results in attenuation of the asthmatic response in mice. Am J Physiol Lung Cell Mol Physiol. 2009;296(5): L763-L770.
25. Shinagawa K, Martin JA, Ploplis VA, et al. Coagulation factor Xa modulates airway remodeling in a murine model of asthma. Am J Respir Crit Care Med. 2007;175(2):136-143. (Pubitemid 46115084)
26. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol. 2004;114(5):997-1008. (Pubitemid 39469133)
27. Shimizu S, Shimizu T, Morser J, et al. Role of the coagulation system in allergic inflammation in the upper airways. Clin Immunol. 2008;129(2):365- 371.
28. Shimizu S, Gabazza EC, Hayashi T, et al. Thrombin stimulates the expression of PDGF in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2000;279(3):L503-L510.
29. Terada M, Kelly EAB, Jarjour NN. Increased thrombin activity after allergen challenge: a potential link to airway remodelling? Am J Respir Crit Care Med. 2004;169(3):373-377. (Pubitemid 38134817)
30. Hauck RW, Schulz C, Schomig A, et al. α-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors. Am J Physiol Lung Cell Mol Physiol. 1999;277:L22-L29. (Pubitemid 29356747)
31. Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010;115(6):1121-1130.
32. Hataji O, Taguchi O, Gabazza EC, et al. Activation of protein C pathway in the airways. Lung. 2002;180(1):47-59. (Pubitemid 36002438)
33. Shimizu S, Gabazza EC, Taguchi O, et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med. 2003;167(10):1416-1426. (Pubitemid 36609728)
34. Moffatt JD, Page CP, Laurent GJ. Shooting for PARs in lung diseases. Curr Opin Pharmacol. 2004;4(3):221-229. (Pubitemid 38585305)
35. Yuda H, Adachi Y, Taguchi O, et al. Activated protein C inhibits bronchial hyper-responsiveness and Th2 cytokine expression in mice. Blood. 2004;103(6):2196-2204. (Pubitemid 38326238)
36. Feistritzer C, Sturn DH, Kaneider NC, et al. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol. 2003;112(2):375-381. (Pubitemid 36981379)
37. Feistritzer C, Mosheimer BA, Sturn DH, et al. Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J Immunol. 2006;176(2):1019-1025. (Pubitemid 43099702)
38. Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010;120(9):3167-3178.
39. Cao C, Gao Y, Li Y, et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest. 2010;120(6):1971- 1980.
40. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by nonanti-coagulant activated protein C. J Exp Med. 2007;204(10):2439-2448. (Pubitemid 47529328)
41. Bir N, Lafarque M, Howard M, et al. Cytoprotective- selective activated protein C attenuates P. aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol. 2011;45(3):632-641.
42. McCarthy NE, Jones HA, Marks NA, et al. Inhaled allergen-driven CD1c upregulation and enhanced antigen uptake by activated human respiratory-tract dendritic cells in atopic asthma. Clin Exp Allergy. 2007;37(1):72-82. (Pubitemid 46011061)
43. Yerkovich ST, Roponen M, Smith ME, et al. Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a TH2-skewed response. J Allergy Clin Immunol. 2009;123(1):209- 216.
44. Takagi T, Taguchi O, Toda M, et al. Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med. 2011;183(1):31-42.
45. Bratke K, Lommatsch M, Kuepper M, et al. Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge. Thorax. 2007;62(2):168-175.
46. Peters T, Henry PJ. Protease-activated receptors and prostaglandins in inflammatory lung disease. Br J Pharmacol. 2009;158(4):1017-1033.
47. Sun G, Stacey MA, Schmidt M, et al. Interaction of mite allergens Der p3 and Der p9 with protease- activated receptor-2 expressed by lung epithelial cells. J Immunol. 2001;167(2):1014-1021. (Pubitemid 32660859)
48. Boitano S, Flynn AN, Sherwood CL, et al. Alternaria alternate serine proteases induce lung inflammation and airway epithelial cell activation via PAR2. Am J Physiol Cell Mol Physiol. 2011; 300(4):L605-L614.
49. Hong JH, Lee SI, Kim KE, et al. German cockroach extract activates protease-activated receptor 2 in human airway epithelial cells. J Allergy Clin Immunol. 2004;113(2):315-319. (Pubitemid 38210556)
50. Knight DA, Lim S, Scaffidi AK, et al. Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol. 2001; 108(5):797-803. (Pubitemid 33096213)
51. Schmidlin F, Amadesi S, Dabbagh K, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol. 2002; 169(9):5315-5321. (Pubitemid 35217205)
52. Ebeling C, Lam T, Gordon JR. Proteinase-activated receptor-2 promotes allergic sensitization to an inhaled antigen through a TNF-mediated pathway. J Immunol. 2007;179(5):2910- 2917.
53. Ebeling C, Forsythe P, Ng J, et al. Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyper-responsiveness through different pathways. J Allergy Clin Immunol. 2005; 115(3):623-630. (Pubitemid 40341720)
54. Arizmedni NG, Abel M, Mihara K. Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. J Immunol. 2011; 186(5):3164-3172.
55. Kornerup KN, Page CP. The role of platelets in the pathophysiology of asthma. Platelets. 2007; 18(5):319-328. (Pubitemid 47123838)
56. Yamamoto H, Nagata M, Tabe K, et al. The evidence of platelet activation in bronchial asthma. J Allergy Clin Immunol. 1993;91:79-87. (Pubitemid 23042183)
57. Kowal K, Pampuch A, Kowal-Bielecka O, et al. Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin Exp Allergy. 2006;36(4):426- 432.
58. Gresele P, Dottorini M, Selli ML, et al. Altered platelet function associated with the bronchial hyper-responsiveness accompanying nocturnal asthma. J Allergy Clin Immunol. 1993;91(4):894- 902.
59. Pitchford SC, Yano H, Lever R, et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol. 2003;112(1): 109-118. (Pubitemid 36819815)
60. Pitchford SC, Momi S, Giannini S, et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood. 2005;105(5):2074- 2081.
61. Lukacs NW, John A, Berlin A, et al. E- and P-selectins are essential for the development of cockroach allergen-induced airway responses. J Immunol. 2002;169(4):2120-2125. (Pubitemid 34857678)
62. Ulfman LH, Joosten DPH, Van Aalst CW, et al. Platelets promote eosinophil adhesion of patients with asthma to endothelium under flow conditions. Am J Respir Cell Mol Biol. 2003;28(4):512- 519.
63. Pitchford SC, Riffo-Vasquez Y, Sousa A, et al. Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood. 2004;103(2):639-647. (Pubitemid 38140099)
64. Jeffery PK, Wardlaw AJ, Nelson FC, et al. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis. 1989;140(6):1745-1753. (Pubitemid 20041063)
65. Pitchford SC, Momi S, Baglioni S, et al. Allergen induces the migration of platelets to lung tissue in allergic asthma. Am J Respir Crit Care Med. 2008;177(6):604-612. (Pubitemid 351442167)
66. Joseph M, Capron A, Ameisen JC, et al. The receptor for IgE on blood platelets. Eur J Immunol. 1986;16(3):306-312. (Pubitemid 16119808)
67. Hasegawa S, Pawankar R, Suzuki K, et al. Functional expression of the high affinity receptor for IgE (FcepsilonRI) in human platelets and its intracellular expression in human megakaryocytes. Blood. 1999;93(8):2543-2551. (Pubitemid 29181186)
68. Vargaftig BB, Lefort J, Chignard M, et al. Platelet-activating factor induces platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol. 1980; 65(2):185-192. (Pubitemid 10058073)
69. Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986;2(8500):189-192. (Pubitemid 16059402)
70. Ishida K, Thomson RJ, Beattie LL, et al. Inhibition of antigen-induced airway hyper-responsiveness, but not acute hypoxia nor airway eosinophilia, by an antagonist of platelet-activating factor. J Immunol. 1990;144(10):3907-3911. (Pubitemid 20171204)
71. Ito S, Noguchi E, Shibasaki M, et al. Evidence for an association between plasma platelet activating factor acetylhydrolase and increased risk of childhood atopic asthma. J Hum Gen. 2002;47(2):99- 101.
72. Stafforini DM, Numao T, Tsodikov A, et al. Deficiency of platelet activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest. 1999;103(7):989-997. (Pubitemid 29169606)
73. Vincent D, Lefort J, Chatelet F, et al. Intratracheal E coli lipopolysaccharide induces platelet-dependent bronchial hyperreactivity. J Appl Physiol. 1993;74(3):1027-1038. (Pubitemid 23118549)
74. Cicala C, Bucci M, De Dominicis G, et al. Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo. Br J Pharmacol. 1999;126(2):478-484. (Pubitemid 29057599)
75. Coyle AJ, Page CP, Atkinson L, et al. The requirement for platelets in allergen-induced late asthmatic airway obstruction: eosinophil infiltration and heightened airway responsiveness in allergic rabbits. Am Rev Respir Dis. 1990;142(3):587- 593.
76. Lellouch-Tubiana A, Lefort J, Simon MT, et al. Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration: modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis. 1988; 137(4):948-954. (Pubitemid 18099314)
77. Robertson DN, Page CP. Effect of platelet agonists on airway reactivity and intrathoracic platelet accumulation. Br J Pharmacol. 1987;92(1):105- 111.
78. Ma Z, Paeck D, Oh CK. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Experimental Allergy. 2009;39(8):1136-1144.
79. Kowal K, Zukowski S, Moniuszko M, et al. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Folia Histochem Cytobiol. 2008;46(2):193-198.
80. Oh CK, Ariue B, Alban RF, et al. PAI-1 promotes extracellular matrix deposition in the airways of murine asthma model. Biochem Biophys Res Commun. 2002;294(5):1155-1160. (Pubitemid 34687171)
81. Kucharewicz I, Mogielnicki A, Kasacka I, et al. Plasmin system regulation in an ovalbumin - induced rat model of asthma. Int Arch Allergy Immunol. 2008;147(3):190-196.
82. Kuramoto E, Nishiuma T, Kobayashi K, et al. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol. 2009; 296(3):L337-L346.
83. Cho SH, Tam SW, Demissie-Sanders S, et al. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol. 2000;165(6):3154-3161.
84. Nakajima T, Inagaki N, Tanaka H, et al. Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcepsilon receptor I cross-linking: an interspecies comparison. Blood. 2002;100(12): 3861-3868. (Pubitemid 35396850)
85. Sejima T, Madoiwa S, Mimuro J, et al. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol. 2005;174(12): 8135-8143. (Pubitemid 40806325)
86. Cho SH, Hall IP, Wheatley A, et al. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol. 2001;108(2):212- 214.
87. Kowal K, Bodzenta-Lukaszyk A, Pampuch A, et al. Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge. Int Arch Allergy Immunol. 2007;144(3):240-246. (Pubitemid 47587611)
88. Ma Z, Jhun B, Jung SY, et al. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol. 2008;121(4):1006-1012.
89. Swaisgood CM, Aronica MA, Swaidani S, et al. Plasminogen is an important regulator in the pathogenesis of a murine model of asthma. Am J Respir Crit Care Med. 2007;176(4):333-342. (Pubitemid 47267466)
90. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost. 2005; 3(1):35-45. (Pubitemid 41647113)
91. Fujiwara A, Taguchi O, Takagi T, et al. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma [published online ahead of print October 25, 2011]. Lung. doi:10.1007/ s00408-011-9337-9.
92. Niven AS, Argyros G. Alternate treatments in asthma. Chest. 2003;123(4):1254-1265. (Pubitemid 36444386)
93. Boyle JP, Smart RH, Shirey JK. Heparin in the treatment of chronic obstructive bronchopulmonary disease. Am J Cardiol. 1964;14:25-28.
94. Fine NL, Shim C, Williams MH. Objective evaluation of heparin in the treatment of asthma. Am Rev Respir Dis. 1968;98(5):886-887.
95. Bardana EJ Jr, Edwards MJ, Pirofsky B. Heparin as treatment for bronchospasm in asthma. Ann Allergy. 1969;27(3):108-113.
96. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med. 1993;329(2):90-95. (Pubitemid 23188822)
97. Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med. 1996;153(5):1702-1707.
98. Ahmed T, Gonzalez BJ, Danta I. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular weight heparin. Am J Respir Crit Care Med. 1999;160(2):576-581. (Pubitemid 29380675)
99. Bowler SD, Smith SM, Laverombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic patients. Am Rev Respir Dis. 1993;147(1):160-163. (Pubitemid 23025933)
100. Diamant Z, Timmers MC, van der Veen H, et al. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med. 1996;153:1790-1795. (Pubitemid 26187901)
101. Kalpaklioglu AF, Demirel YS, Saryal S, et al. Effect of pretreatment with heparin on pulmonary and cutaneous response. J Asthma. 1997;34(4): 337-343. (Pubitemid 27365645)
102. Pavord I, Mudassar T, Bennett J, et al. The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Eur J Respir. 1996;9(2):217-219. (Pubitemid 26068614)